Alchemab Therapeutics has raised $80m to advance research originating at University of Oxford, Johns Hopkins University and Mount Sinai Hospital.
Alchemab Therapeutics, a UK-based developer of antibody therapies that is based on research at University of Oxford, Johns Hopkins University and Mount Sinai Hospital, has collected £60m ($82m) in series A financing.
RA Capital Management led the round, which also included Lightstone Ventures, Data Collective VC, DHVC, SV Health Investors and Dementia Discovery Fund.
Founded in 2019, Alchemab is working on a target-agnostic drug discovery platform that analyses the antibody repertoires of patients who exhibit an unexpected resistance to disease despite genetic disposition or other risk factors.
This way, Alchemab uncovers naturally protective antibodies that could form the basis of therapies.
The company is initially focused on hard-to-treat neurodegenerative diseases and cancers, with multiple programmes in preclinical development. It secured an Innovate UK grant last month to develop an antibody therapy for Huntington’s disease.
The cash injection allows Alchemab to accelerate its platform development.
…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
